BioCentury | Feb 12, 2020
Emerging Company Profile

Volastra raises $12M seed led by Polaris to shut down metastasis

...in.” Cantley is the Meyer director of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medical College...
...Inc. New York City, N.Y. Technology: Chromosomal instability-targeted therapies to halt metastasis Origin of technology: Weill Cornell Medical College...
...Clinical status: Preclinical Founded: 2020 By Lewis Cantley, Olivier Elemento and Samuel Bakhoum University collaborators: Weill Cornell Medical College...
BioCentury | Feb 11, 2020
Product Development

Adverum gains on Phase I data showing efficacy for wet AMD gene therapy

...therefore delivered via surgery. Kiss is director of clinical research in the ophthalmology department at Weill Cornell Medical College...
BioCentury | Apr 23, 2019
Distillery Therapeutics

The iron replacement drug Feraheme as a leukemia therapy

...Jan Grimm, Memorial Sloan Kettering Cancer Center, New York, N.Y. email: grimmj@mskcc.org CONTACT: Monica Guzman, Weill Cornell Medical College...
BioCentury | Feb 28, 2019
Emerging Company Profile

Gotham’s RNA utility belt

...Therapeutics Inc., Lexington, Mass. Gotham Therapeutics Corp., New York, N.Y. Storm Therapeutics Ltd., Cambridge, U.K. Weill Cornell Medical College...
BioCentury | Feb 1, 2019
Preclinical News

Targeting mycolate and non-mycolate lipids for TB

...A team led by Texas A&M University and Weill Cornell Medical College researchers have reported in a Science paper...
...also in its simultaneous inhibition of mycolate synthesis. Nathan is a professor of microbiology at Weill Cornell Medical College...
BioCentury | Nov 9, 2018
Clinical News

Adverum reviewing capsid after discontinuing AAT gene therapy

...factor (PGF; PLGF). Predecessor company Annapurna Therapeutics S.A.S. obtained rights to ADVM-043 and ADVM-053 from Weill Cornell Medical College...
BioCentury | Nov 2, 2018
Clinical News

Adverum reviewing capsid after discontinuing AAT gene therapy

...factor (PGF; PLGF). Predecessor company Annapurna Therapeutics S.A.S. obtained rights to ADVM-043 and ADVM-053 from Weill Cornell Medical College...
BioCentury | Jun 7, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: May 2018

...a biotinoyl-deoxyadenosine-based inhibitor of M. tuberculosis BirA could help treat TB and reduce drug resistance. Weill Cornell Medical College...
BioCentury | May 3, 2018
Distillery Therapeutics

Infectious disease

...et al. Sci. Transl. Med. ; published online April 25, 2018 doi:10.1126/scitranslmed.aal1803 CONTACT: Dirk Schnappinger, Weill Cornell Medical College...
BioCentury | Feb 27, 2018
Emerging Company Profile

Stressing out cancer

...of the newco. Glimcher’s studies have focused on the stress response since her tenure at Weill Cornell Medical College...
...Institute, Boston, Mass. Quentis Therapeutics Inc., New York, N.Y. Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), Tarrytown, N.Y. Weill Cornell Medical College...
Items per page:
1 - 10 of 191
BioCentury | Feb 12, 2020
Emerging Company Profile

Volastra raises $12M seed led by Polaris to shut down metastasis

...in.” Cantley is the Meyer director of the Sandra and Edward Meyer Cancer Center at Weill Cornell Medical College...
...Inc. New York City, N.Y. Technology: Chromosomal instability-targeted therapies to halt metastasis Origin of technology: Weill Cornell Medical College...
...Clinical status: Preclinical Founded: 2020 By Lewis Cantley, Olivier Elemento and Samuel Bakhoum University collaborators: Weill Cornell Medical College...
BioCentury | Feb 11, 2020
Product Development

Adverum gains on Phase I data showing efficacy for wet AMD gene therapy

...therefore delivered via surgery. Kiss is director of clinical research in the ophthalmology department at Weill Cornell Medical College...
BioCentury | Apr 23, 2019
Distillery Therapeutics

The iron replacement drug Feraheme as a leukemia therapy

...Jan Grimm, Memorial Sloan Kettering Cancer Center, New York, N.Y. email: grimmj@mskcc.org CONTACT: Monica Guzman, Weill Cornell Medical College...
BioCentury | Feb 28, 2019
Emerging Company Profile

Gotham’s RNA utility belt

...Therapeutics Inc., Lexington, Mass. Gotham Therapeutics Corp., New York, N.Y. Storm Therapeutics Ltd., Cambridge, U.K. Weill Cornell Medical College...
BioCentury | Feb 1, 2019
Preclinical News

Targeting mycolate and non-mycolate lipids for TB

...A team led by Texas A&M University and Weill Cornell Medical College researchers have reported in a Science paper...
...also in its simultaneous inhibition of mycolate synthesis. Nathan is a professor of microbiology at Weill Cornell Medical College...
BioCentury | Nov 9, 2018
Clinical News

Adverum reviewing capsid after discontinuing AAT gene therapy

...factor (PGF; PLGF). Predecessor company Annapurna Therapeutics S.A.S. obtained rights to ADVM-043 and ADVM-053 from Weill Cornell Medical College...
BioCentury | Nov 2, 2018
Clinical News

Adverum reviewing capsid after discontinuing AAT gene therapy

...factor (PGF; PLGF). Predecessor company Annapurna Therapeutics S.A.S. obtained rights to ADVM-043 and ADVM-053 from Weill Cornell Medical College...
BioCentury | Jun 7, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: May 2018

...a biotinoyl-deoxyadenosine-based inhibitor of M. tuberculosis BirA could help treat TB and reduce drug resistance. Weill Cornell Medical College...
BioCentury | May 3, 2018
Distillery Therapeutics

Infectious disease

...et al. Sci. Transl. Med. ; published online April 25, 2018 doi:10.1126/scitranslmed.aal1803 CONTACT: Dirk Schnappinger, Weill Cornell Medical College...
BioCentury | Feb 27, 2018
Emerging Company Profile

Stressing out cancer

...of the newco. Glimcher’s studies have focused on the stress response since her tenure at Weill Cornell Medical College...
...Institute, Boston, Mass. Quentis Therapeutics Inc., New York, N.Y. Regeneron Pharmaceuticals Inc. (NASDAQ:REGN), Tarrytown, N.Y. Weill Cornell Medical College...
Items per page:
1 - 10 of 191